Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Inventiva ( (IVA) ) has issued an update.
Inventiva announced on April 22, 2026, that it has expanded its leadership team with the appointments of Axel-Sven Malkomes as Chief Financial Officer, Susan Coles as Chief Legal Officer, and Pamela Herbster as Chief People Officer. The reshuffle includes new strategic roles for long-serving executives Jean Volatier and Nathalie Harroy, who will remain with the company.
The hires come as Inventiva prepares for a key Phase 3 data readout for its lead MASH candidate lanifibranor, expected in the fourth quarter of 2026, signaling a pivot toward potential regulatory filings and commercialization. By adding seasoned leaders with deep experience in finance, legal, governance, and human capital, Inventiva is bolstering its operational readiness and governance structure ahead of a potentially transformative period for the company and its stakeholders.
The most recent analyst rating on (IVA) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Inventiva stock, see the IVA Stock Forecast page.
Spark’s Take on IVA Stock
According to Spark, TipRanks’ AI Analyst, IVA is a Neutral.
Overall score is held down primarily by weak financial performance (large and widening losses, ongoing cash burn, negative equity and higher debt) and bearish technical momentum. The earnings call provides a partial offset via clear Phase III execution milestones and defined readout timing with near-term funding visibility, while valuation is not supportive due to loss-making fundamentals and no dividend.
To see Spark’s full report on IVA stock, click here.
More about Inventiva
Inventiva is a clinical-stage biopharmaceutical company specializing in oral small-molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH) and other diseases with significant unmet medical need. The company is listed on Euronext Paris and the Nasdaq Global Market under the ticker IVA and is running the pivotal Phase 3 NATiV3 trial of lanifibranor in adult MASH patients.
Average Trading Volume: 411,101
Technical Sentiment Signal: Buy
Current Market Cap: $1.16B
Learn more about IVA stock on TipRanks’ Stock Analysis page.